Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22505581 | 0.80 | SIGMAR1 (0.40) | ILKLMNA | |
| SCHEMBL21964594 | 0.77 | POLB (0.40) | POLBILKSMN1; SMN2SYKKEAP1 | |
| SCHEMBL1924976 | 0.77 | ILK (0.39) | ILKSMN1; SMN2KEAP1LMNA | |
| SCHEMBL691318 | 0.73 | POLB (0.51) | L3MBTL1POLBMAPTLMNA | |
| SCHEMBL21960869 | 0.73 | L3MBTL1 (0.42) | L3MBTL1POLBMAPT | |
| SCHEMBL30860313 | 0.73 | KDM4E (0.41) | ILKMAPTLMNA | |
| SCHEMBL21960837 | 0.72 | L3MBTL1 (0.41) | L3MBTL1POLBMAPT | |
| SCHEMBL15048578 | 0.72 | HPGDS (0.46) | L3MBTL1ILK | |
| SCHEMBL19635528 | 0.72 | POLB (0.47) | L3MBTL1POLBSMN1; SMN2LMNA | |
| SCHEMBL17127621 | 0.71 | P2RX7 (0.45) | L3MBTL1POLBSMN1; SMN2KEAP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | L3MBTL1 2728/4885POLB 1088/4885CRHBP 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.